On 28 April 2016, orphan designation (EU/3/16/1653) was granted by the European Commission to Galderma R&D, France, for resiquimod for the treatment of cutaneous T-cell lymphoma.
The sponsorship was transferred to Galderma International, France in January 2022.
Treatment of cutaneous T-cell lymphoma
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
|January 2022||The sponsorship was transferred to Galderma International, France.|
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: